Haitao Ji

List of Publications by Year in Descending Order

78 papers	2,444 citations	29 h-index	47 g-index
85 ext. papers	2,730 ext. citations	5.9 avg, IF	5.02 L-index

#	Paper	IF	Citations
78	New ZW4864 Derivatives as Small-Molecule Inhibitors for the Catenin/BCL9 Protein-Protein Interaction.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 865-870	4.3	1
77	Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2021**, 64, 5886-5904	8.3	5
76	Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2021**, 64, 11195-11218	8.3	4
75	Direct targeting of catenin in the Wnt signaling pathway: Current progress and perspectives. *Medicinal Research Reviews*, **2021**, 41, 2109-2129	14.4	17
74	Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2021**, 64, 12109-12131	8.3	4
73	Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 51, 128354	2.9	0
72	Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity. *Oncogene*, **2020**, 39, 5187-5200	9.2	3
71	Inhibition of catenin/B cell lymphoma 9 protein-protein interaction using helix-mimicking sulfono-AApeptide inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 10757-10762	11.5	42
70	Optimization of Peptidomimetics as Selective Inhibitors for the Catenin/T-Cell Factor Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2019**, 62, 3617-3635	8.3	13
69	Targeting the Side-Chain Convergence of Hydrophobic Helical Hot Spots To Design Small-Molecule Mimetics: Key Binding Features for , + 3, and + 7. *Journal of Medicinal Chemistry*, **2019**, 62, 9906-9917	8.3	3
68	Rhodium-Catalyzed [4 + 1] Cyclization via C-H Activation for the Synthesis of Divergent Heterocycles Bearing a Quaternary Carbon. *Journal of Organic Chemistry*, **2018**, 83, 4650-4656	4.2	42
67	Ruthenium(II)-Catalyzed Regio- and Stereoselective C-H Allylation of Indoles with Allyl Alcohols. *Organic Letters*, **2018**, 20, 2224-2227	6.2	35
66	Structure-Based Optimization of Small-Molecule Inhibitors for the Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2018**, 61, 2989-3007	8.3	23
65	Rhodium(iii)-catalyzed C-H allylation of indoles with allyl alcohols via hydroxide elimination. *Organic and Biomolecular Chemistry*, **2018**, 16, 5691-5698	3.9	18
64	Ruthenium-Catalyzed C-H Allylation of Alkenes with Allyl Alcohols via C-H Bond Activation in Aqueous Solution. *Journal of Organic Chemistry*, **2018**, 83, 12094-12102	4.2	12
63	AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells. *Molecular Carcinogenesis*, **2018**, 57, 1300-1310	5	15
62	Hot Spot-Based Design of Small-Molecule Inhibitors for Protein-Protein Interactions **2018**, 53-71		0

61	A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 157-169	8.3	21
60	Direct heteroarylation of amides (to nitrogen) and ethers through a benzaldehyde-mediated photoredox reaction. *Chemical Science*, **2016**, 7, 2111-2118	9.4	62
59	Structure-Based Design of 1,4-Dibenzoylpiperazines as Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors. *ACS Medicinal Chemistry Letters*, **2016**, 7, 508-13	4.3	26
58	Rational design of selective small-molecule inhibitors for catenin/B-cell lymphoma 9 protein-protein interactions. *Journal of the American Chemical Society*, **2015**, 137, 12249-60	16.4	46
57	AlphaScreen selectivity assay for catenin/B-cell lymphoma 9 inhibitors. *Analytical Biochemistry*, **2015**, 469, 43-53	3.1	19
56	Discovery of Selective Small-Molecule Inhibitors for the Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety. *Journal of Medicinal Chemistry*, **2015**, 58, 4678-92	8.3	39
55	Protocol for fragment hopping. *Methods in Molecular Biology*, **2015**, 1289, 57-73	1.4	3
54	Hot spot-based design of small-molecule inhibitors for protein-protein interactions. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2546-54	2.9	106
53	Targeting the Tcf4 G13ANDE17 binding site to selectively disrupt catenin/T-cell factor protein-protein interactions. *ACS Chemical Biology*, **2014**, 9, 193-201	4.9	39
52	The mobility of a conserved tyrosine residue controls isoform-dependent enzyme-inhibitor interactions in nitric oxide synthases. *Biochemistry*, **2014**, 53, 5272-9	3.2	13
51	nNOS inhibition during profound asphyxia reduces seizure burden and improves survival of striatal phenotypic neurons in preterm fetal sheep. *Neuropharmacology*, **2014**, 83, 62-70	5.5	18
50	Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1333-43	3.4	14
49	Case Study 3: Fragment Hopping to Design Highly Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors. *Methods and Principles in Medicinal Chemistry*, **2013**, 279-296	0.4	
48	Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. *Experimental Neurology*, **2013**, 250, 282-92	5.7	18
47	Rational design of small-molecule inhibitors for catenin/T-cell factor protein-protein interactions by bioisostere replacement. *ACS Chemical Biology*, **2013**, 8, 524-9	4.9	39
46	High-Throughput Selectivity Assays for Small-Molecule Inhibitors of Catenin/T-Cell Factor Protein-Protein Interactions. *ACS Medicinal Chemistry Letters*, **2013**, 4, 306-11	4.3	21
45	Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. *Antioxidants and Redox Signaling*, **2013**, 19, 433-47	8.4	41
44	Intramolecular hydrogen bonding: a potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 2435-43	3.4	28

43	Acid-Facilitated Debenzylation of N-Boc, N-Benzyl Double Protected 2-Aminopyridinomethylpyrrolidine Derivatives. *Tetrahedron*, **2012**, 68, 1359-1366	2.4	11
42	Antenatal insults modify newborn olfactory function by nitric oxide produced from neuronal nitric oxide synthase. *Experimental Neurology*, **2012**, 237, 427-34	5.7	10
41	Selective monocationic inhibitors of neuronal nitric oxide synthase. Binding mode insights from molecular dynamics simulations. *Journal of the American Chemical Society*, **2012**, 134, 11559-72	16.4	20
40	New homogeneous high-throughput assays for inhibitors of β-catenin/Tcf protein-protein interactions. *Analytical Biochemistry*, **2012**, 424, 57-63	3.1	9
39	Improved synthesis of chiral pyrrolidine inhibitors and their binding properties to neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2011**, 54, 6399-403	8.3	8
38	Involvement of neuronal nitric oxide synthase in ongoing fetal brain injury following near-term rabbit hypoxia-ischemia. *Developmental Neuroscience*, **2011**, 33, 288-98	2.2	18
37	Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: comparison between JI-8 and 7-nitroindazole. *Developmental Neuroscience*, **2011**, 33, 312-9	2.2	28
36	Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model. *Journal of the American Chemical Society*, **2010**, 132, 5437-42	16.4	46
35	Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. *Journal of Medicinal Chemistry*, **2010**, 53, 7804-24	8.3	40
34	Fragment-Based Drug Design: Considerations for Good ADME Properties **2010**, 417-485		
33	Evolutionary trace analysis of CYP51 family: implication for site-directed mutagenesis and novel antifungal drug design. *Journal of Molecular Modeling*, **2010**, 16, 279-84	2	17
32	Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization. *ChemMedChem*, **2010**, 5, 390-7	3.7	32
31	Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 6526-37	3.4	15
30	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2942-5	2.9	28
29	Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors. *European Journal of Medicinal Chemistry*, **2010**, 45, 3531-40	6.8	47
28	Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase. *Beilstein Journal of Organic Chemistry*, **2009**, 5, 28	2.5	11
27	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. *Annals of Neurology*, **2009**, 65, 209-17	9.4	71
26	Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives. *Archiv Der Pharmazie*, **2009**, 342, 732-9	4.3	26

25	Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design. *Journal of Computer-Aided Molecular Design*, **2009**, 23, 375-89	4.2	14
24	Discovery of highly potent novel antifungal azoles by structure-based rational design. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5965-9	2.9	29
23	New azoles with potent antifungal activity: design, synthesis and molecular docking. *European Journal of Medicinal Chemistry*, **2009**, 44, 4218-26	6.8	44
22	Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 2371-80	3.4	36
21	Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. *Journal of Medicinal Chemistry*, **2009**, 52, 779-97	8.3	78
20	Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 3487-95	5.9	75
19	Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 2060-6	8.3	18
18	Hypoxia-ischemia causes persistent movement deficits in a perinatal rabbit model of cerebral palsy: assessed by a new swim test. *International Journal of Developmental Neuroscience*, **2009**, 27, 549-57	2.7	27
17	L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 4533-7	8.3	10
16	Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. *Journal of the American Chemical Society*, **2008**, 130, 3900-14	16.4	88
15	New homocamptothecins: synthesis, antitumor activity, and molecular modeling. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 1493-510	3.4	22
14	Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for gamma-aminobutyric acid aminotransferase. Conformational probes for GABA binding. *Biochemistry*, **2007**, 46, 13819-28	3.2	35
13	Construction of a three-dimensional pharmacophore for Bcl-2 inhibitors by flexible docking and the multiple copy simultaneous search method. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 6407-17	3.4	21
12	3D-QSAR and molecular docking studies on benzothiazole derivatives as Candida albicans N-myristoyltransferase inhibitors. *European Journal of Medicinal Chemistry*, **2007**, 42, 477-86	6.8	26
11	Synthesis and antifungal activities of novel 2-aminotetralin derivatives. *Journal of Medicinal Chemistry*, **2007**, 50, 5293-300	8.3	48
10	Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 6254-63	8.3	22
9	Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3681-90	3.4	6
8	Remote protection prevents unwanted cyclizations with 2-aminopyridines. *Tetrahedron Letters*, **2006**, 47, 6113-6115	2	15

7	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. *Journal of Medicinal Chemistry*, **2006**, 49, 2512-25	8.3	139
6	Selective neuronal nitric oxide synthase inhibitors. *Current Topics in Medicinal Chemistry*, **2005**, 5, 603-24	3	60
5	Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions. *Journal of Biomolecular Structure and Dynamics*, **2004**, 22, 91-9	3.6	53
4	Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. *Journal of Medicinal Chemistry*, **2003**, 46, 474-85	8.3	101
3	Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. *Journal of Medicinal Chemistry*, **2003**, 46, 5700-11	8.3	65
2	A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. *Journal of Medicinal Chemistry*, **2000**, 43, 2493-505	8.3	185
1	A method of active conformation search based on active and inactive analogues and its application to allylamine antimycotics. *Science in China Series C: Life Sciences*, **1999**, 42, 538-47		